EMBLEM and Enzymicals AG collaborate

22. February 2021

EMBLEM and Enzymicals AG announce a license and collaboration agreement to improve enzymatic production of chemicals by the use of innovative computational tools.

The parties will leverage Transform-MinER, a novel in silico tool package developed at EMBL’s European Bioinformatics Institute, to identify novel high value-added biosynthetic enzyme reactions with relevance to Enzymicals’ proprietary product portfolio. This will enable Enzymicals to develop competitive production pathways for a range of chemicals.